The system processes a standard blood draw to concentrate the body’s natural cell-derived particles. By utilizing a patient's own biology, practitioners can integrate these concentrated components into individualized aesthetic protocols. According to CEO Erik Dowell, the move represents a logical progression for the brand, leveraging an established global platform to offer deeper customization in clinical settings.

Extracellular vesicles are currently a focal point of ongoing scientific research, and this device brings that focus directly into the skin-booster market. The technology serves as a new tool for providers looking to move beyond traditional fillers, offering a tailored preparation for both hair and scalp care applications. Aesthetic Management Partners continues to position these blood-derived treatments as a central component of their clinical support offerings.